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1. Introduction
Helicase and primase are required during DNA replica-
tion because DNA is an antiparallel duplex and because no 
replicative DNA polymerase is able to initiate polymers de 
novo. Primase is a specialized DNA-dependent RNA poly-
merase that generates short oligoribonucleotide polymers de 
novo that can be elongated by DNA polymerase.1, 2 During 
DNA replication, primase initiates the leading strand synthe-
sis at least once and the lagging strand synthesis many times. 
Even though all autonomous life forms store their genetic in-
formation in duplex DNA and use a primase to initiate leading 
and lagging strand DNA synthesis, the primases from archaea 
and eukaryotes are structurally unrelated to the primases from 
prokaryotes.3, 4 In Escherichia coli, conditionally lethal mu-
tations in the primase gene yield lethal phenotypes under the 
non-permissive conditions, demonstrating the essentiality of 
the enzyme.5, 6 The indispensable function of primase and the 
structural divergence of the eukaryotic and prokaryotic pri-
mases have led to the identifi cation of the enzyme as a target 
for novel antibiotic development.7, 8
The DnaG protein from E. coli is the model eubacterial 
primase because its structure and function have been exten-
sively characterized. It has been demonstrated that E. coli 
DnaG primase is slow, binds ssDNA as a dimer, and that in-
teraction with DnaB helicase stimulates its catalytic activ-
ity over 15-fold.9–12 E. coli DnaG primase specifi cally initi-
ates RNA primer synthesis complementary to the trinucleotide 
5′-d(CTG)-3′ in vitro, and E. coli Okazaki fragment initia-
tion maps to a d(CTG) on the chromosomal template strand 
in vivo.13, 14
DnaB helicase from E. coli is the model eubacterial heli-
case that unwinds duplex DNA at the replication fork so that 
the two strands can be replicated by the combination of pri-
mase and DNA polymerase.15 In E. coli, conditionally lethal 
mutations in the dnaB gene yielded lethal phenotypes under 
the non-permissive conditions, demonstrating the essentiality 
of the gene product for replication elongation and initiation.16–
20 During the initiation phase of replication, E. coli DnaB he-
licase interacts with DnaA origin-binding protein, DnaC heli-
case loading protein, and primase.21, 22 During the elongation 
phase, dimeric DNA polymerase III is tethered to the helicase 
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havior with a Ki of 10.0 ± 0.5 μM. At physiological ATP concentration, myricetin inhibits E. coli DnaB helicase with an in-
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via its tau subunit and primase repeatedly and transiently in-
teracts with the helicase to initiate lagging strand synthesis.23, 
24 During the termination phase, the replication machinery 
is prevented from over-replicating the genome by the inhibi-
tory interaction between the Tus protein and DnaB helicase.25 
As the central hub of the replication machinery and given the 
structural divergence of the eukaryotic and prokaryotic fork 
helicases, DnaB is considered to be a novel target for antibi-
otic development.
High-throughput assays have been developed for helicase 
activity, primase activity, and helicase-stimulated primase ac-
tivity to identify novel inhibitors of these two enzymes.7, 26–
28 Primase activity assays have been used to identify several 
natural product inhibitors, such as a bicyclic macrolide, two 
phenolic saccharides, and a group of synthetic compounds 
identifi ed from a series of virtual and real screens.8, 29, 30 The 
phenolic saccharides are not good leads because they inhibit 
primase activity through their ability to bind to ssDNA and 
thereby occlude primase. Helicase activity assays have iden-
tifi ed inhibitors from among the known families of fl avonols 
and triaminotriazines.31, 32 These families of compounds in-
hibit many helicases and/or kinases.31–33
Flavonoids provide fl avor and color to all parts of 
plants. Over 5,000 different fl avonoids, including myricetin 
and quercetin (Figure 1), have been described and some of 
them have been tested for biological activity.34 Many fl avo-
noids have anti-carcinogenic and antibacterial activities but 
the sites of action are known for only a few.35 One of the 
exceptions is that quercetin’s antimicrobial activity can be 
attributed in part to its inhibition of gyrase. Myricetin has 
been shown to have antimicrobial activity but it has not been 
possible to attribute its effect to any one target. Determin-
ing its target has been diffi cult because fl avonoids tend to 
aggregate, adhere to the container surface, and immobilize 
the enzyme being assayed so that it is inactivated by a non-
drug-like mechanism.36, 37 Nevertheless, careful analysis has 
shown that myricetin and quercetin inhibit a variety of DNA 
polymerases, RNA polymerases, reverse transcriptases, and 
telomerases.38–41 
In the present study, it was discovered that DnaB heli-
case activity was 60 times more sensitive to myricetin than 
was primase activity. In fact, primase was the least myrice-
tin-sensitive of all polymerases tested so far. The myricetin 
inhibition kinetics of the DnaB ATPase activity were consis-
tent with simple noncompetitive inhibition with physiological 
amounts of the substrate ATP.
2. Results
The purpose of this study was to determine the extent to 
which myricetin was capable of inhibiting E. coli DnaB heli-
case, primase, and DnaB-stimulated primase activity. The re-
sults showed that DnaB helicase was much more sensitive to 
myricetin than was primase.
2.1. Myricetin inhibition of DnaB ATPase activity
After some preliminary experiments to establish the best 
range of concentrations, the inhibition of DnaB ATPase ac-
tivity was analyzed as a function of ATP and myricetin. In the 
absence of myricetin (Figure 2a and b), the ATP concentra-
tion dependence exhibited hyperbolic saturation kinetics with 
a KM of 31 μM ATP and Vmax = 2870 nM/s (Table 1). These 
were similar to reported values.42, 43 Hyperbolic kinetics in-
dicated that all of the ATP active sites were equal and non-
interacting even though the enzyme has six identical sub-
units per functional complex. As the myricetin was increased 
to 12 μM, the apparent Vmax decreased 2.7-fold whereas the 
apparent KM decreased 11-fold. The decrease in the appar-
ent KM was not consistent with competition between ATP and 
myricetin for the active site. Simple competitive inhibition 
would have increased the KM according to the relationship of 
K′M = KM (1 + [I]/Ki), where K′M is the apparent KM and Ki 
is the median inhibition concentration. When myricetin was 
increased to 30 μM, the apparent KM and apparent Vmax de-
creased by about the same amount indicating that the kinetic 
affi nity for ATP was no longer being so dramatically affected. 
Higher myricetin concentration led to a continued decrease 
in apparent Vmax but an increase in the apparent KM, which 
was fi nally consistent with some small degree of competitive 
inhibition. 
The decrease in apparent Vmax suggested that it may be 
due to noncompetitive inhibition, in which the inhibitor is 
able to bind to both the free enzyme and the enzyme–substrate 
complex to create a “dead end” complex that is inactive. Sim-
ple noncompetitive inhibition decreases the Vmax according to 
the relationship of V ′max = Vmax/(1 + [I]/Ki), where V ′max is the 
apparent Vmax and Ki is the median inhibition concentration. 
Figure 1. The structures of (a) myricetin and (b) quercetin differ with regard to the hydroxyls on carbons 3 and 5′. Tests with a variety of fl avonoids revealed that 
the 3′ and 5′ hydroxyls of myricetin were very important for its ability to inhibit RSF1010 RepA helicase better than the other fl avonoids.57 
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The mathematical inversion of this equation (1/V ′max = 1/
Vmax/(1 + [I]/Ki) indicates that a plot of 1/V ′max versus [I] 
will be linear if it conforms to noncompetitive inhibition 
and that the slope and y-intercept can be used to determine 
the inhibition constant. When the data were so plotted, they 
yielded a linear relationship (Figure 2c circles) and a Ki of 
10.0 ± 0.5 μM. Therefore, the decrease in enzyme activity as 
a function of myricetin at saturating ATP was due to noncom-
petitive inhibition.
To determine the inhibitor concentration that causes 
50% inhibition, IC50, the ATPase activity was replotted ver-
sus myricetin concentration (Figure 2d). At the highest ATP 
concentrations, 150 μM (solid line) and 1 mM (dashed 
line), the data conformed to the inhibition equation: % 
activity = Ymax − Ymax [I]/(IC50 + [I]). Fitting the 150 μM ATP 
data revealed that the Ymax was 2340 ± 50 nM/s and IC50 was 
10.2 ± 0.6 μM myricetin with an R2 of 0.997. At 1 mM ATP, 
the Ymax was 2510 ± 110 nM/s and IC50 was 11.3 ± 1.6 μM 
myricetin with an R2 of 0.986. These values were statistically 
the same as the Ki, showing that the dominant inhibition mech-
anism at high and saturating ATP was noncompetitive. An ex-
amination of the myricetin effect (Figure 2d) further showed 
that myricetin stimulated ATPase when its concentration was 
less than 12 μM and the ATP concentration was less than 
10 μM. At these low non-physiological ATP concentrations 
(Figure 2d), the KM effects (Figure 2c) indicate that myrice-
tin binding to non-active sites was able to enhance ATPase ac-
tivity by increasing the enzyme’s kinetic affi nity for ATP more 
than its Vmax decreases.
2.2. Myricetin inhibition of primase alone
The ability of myricetin to inhibit primase activity in the 
absence of DnaB was tested because it is an inhibitor of a va-
riety of DNA polymerases, RNA polymerases, and reverse 
transcriptases.38–41 This was also an important control for the 
more physiologically relevant reaction of DnaB-stimulated 
primer synthesis. When myricetin was added to the reaction 
containing primase and its substrates, it barely inhibited in a 
concentration-dependent manner (Figure 3). It was not possi-
ble to test higher myricetin concentrations due to myricetin’s 
low solubility. Even though the error in each measurement is 
about 5%, the same scale as the effect, fi tting of the data to the 
Figure 2. The effect of ATP and myricetin on E. coli DnaB ATPase. In panels a and b, the myricetin concentrations were 0 μM (•), 6 (○), 12 (■), 30 (□), and 60 
(▲). In panel c, apparent kinetic constants from the data were plotted versus myricetin concentration. In panel d, the ATPase activity was replotted versus myric-
etin concentration such that the ATP concentrations were 1 μM (•), 3 μM (■), 10 μM (▲), 150 μM (○), and 1 mM ATP (□). 
Table 1. Apparent Michaelis–Menten constants for E. coli DnaB he-
licase in the presence of myricetin 
Myricetin (μM) V ′max(μM/s) K′M(μM) R
2
0 2.87 ± 0.09 31 ± 3 0.998
6 1.64 ± 0.08 17 ± 3 0.989
12 1.06 ± 0.07 2.9 ± 0.9 0.958
30 0.61 ± 0.04 2.3 ± 0.8 0.952
60 0.35 ± 0.05 4.5 ± 3.1 0.801
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inhibition equation revealed that the IC50 was 700 ± 300 μM 
myricetin. The consequence was that myricetin inhibited pri-
mase activity 60 times weaker than it inhibited DnaB ATPase 
activity and much weaker than the low micromolar IC50’s for 
DNA polymerases, RNA polymerases, reverse transcriptases, 
and telomerases. 38–41 It may be relevant that the structure of 
bacterial primase differs from those palm-type nucleic acid 
polymerases in that it has a ‘cashew-shaped’ active site shared 
by no other polymerase family.44, 45 
2.3. Myricetin inhibition of DnaB-stimulated primer 
synthesis
Primase and DnaB stimulate each other’s activities.46 Of 
these cross-reactivities, the DnaB stimulation of primer syn-
thesis activity is the most relevant to DNA replication because 
DNA polymerase cannot synthesize DNA without the result-
ing primer. Therefore, primer synthesis by primase was mea-
sured with and without helicase as a function of myricetin 
concentration. Unfortunately, the controls without myricetin 
but with DMSO showed that 0.5–4% DMSO, which would be 
added with 10–40 μM myricetin as its solvent, completely in-
hibited the helicase stimulation when it was present at its most 
stimulatory ratio relative to the primase. 12, 13, 46 This reduced 
level of primase activity was the same as primase alone and 
may refl ect a slight stimulation effect by the myricetin (Figure 
3). Therefore, DMSO may not cause primase and helicase to 
dissociate from each other, but rather the presence of helicase 
may alter the ability of primase to be inhibited by myricetin.
3. Discussion
Myricetin is one of the six major fl avonoids, plant pig-
ments found in many foods and beverages, that are nutrition-
ally interesting primarily for their antioxidant activities.47 We 
show here that myricetin inhibits homohexameric E. coli DnaB 
with a Ki and IC50 of about 10 μM. The results also showed 
that myricetin would be an effective inhibitor at the log-phase-
growth-phase ATP concentration of 3 mM.48 The inhibitory 
mechanism was noncompetitive, indicating that myricetin does 
not bind to the active site. Even though the mechanism for 
ATP hydrolysis by hexameric helicases is complex, the current 
model for DnaB is that ATP can bind and be hydrolyzed in the 
active site of every other subunit.49 Binding of ATP to the re-
maining three subunits is weaker and negatively cooperative.50 
For these reasons, it is interesting to speculate that myricetin is 
binding to the unfi lled active sites to shut down the hydrolytic 
activity of the ATP-bound active sites.
The unwinding mechanism of the T7 gene 4 protein, a 
DnaB homolog, has been proposed to pass ssDNA from one 
subunit to another within the toroid as each adjacent subunit 
binds ATP, hydrolyzes it, and then releases ADP and phos-
phate.51 When myricetin concentration is low, it must bind at 
or near the ATP pocket of one subunit such that it stimulates 
ATP synthesis in adjacent subunits. When myricetin concen-
tration is moderate or high, it must bind to more than one sub-
unit to lock the homohexamer into an inactive complex.
Other studies have shown that myricetin inhibited 
RSF1010 RepA, a distant hexameric helicase homolog, with a 
Ki = 23 μM and IC50 = 50 μM.
31 This is substantially weaker 
than the inhibition of DnaB helicase described here. The 
RepA myricetin inhibition kinetics also differed from those 
with DnaB in that they were competitive. Nevertheless, of the 
several fl avonoids this group tested, myricetin was the most 
effective at inhibiting cellular growth. The minimal inhibi-
tory concentration for E. coli was 0.50 mg/mL and for Bacil-
lus subtilis was 0.25 mg/mL.31
RSF1010 RepA differs from both bacterial DnaB and 
T7 gene 4 protein in that it lacks a distinct N-terminal do-
main.52, 53 Specifi cally, DnaB is composed of three domains: 
the N-terminal domain (NTD or DnaBα), the ATPase shoulder 
(DnaBβ), and the C-terminal hexamerization domain (DnaBγ). 
Bacterial primase binds to the linker that connects the DnaB 
NTD with its ATPase domain.54 Even though RepA inter-
acts with RepC initiator protein and RepB′ primase, neither 
of those two enzymes is related by sequence to either E. coli 
DnaA or DnaG primase. Our results indicate that RSF1010 
RepA is not a good model for DnaB perhaps because it lacks 
an N-terminal interaction domain.
There is only one crystal structure of inhibitory myrice-
tin bound to one of its targets phosphatidylinositol-3-kinase 
(PIK3) (1E90.pdb).55 Myricetin and 13 other fl avonoids are 
low micromolar competitive inhibitors of PIK3, which is in-
volved in signal transduction.56 Given that they inhibited with 
similar affi nities, it was remarkable to fi nd that every one of 
the fi ve co-crystallized fl avonoids adopted a different ori-
entation within the PIK3 ATP site. For instance, myricetin 
bound at a different angle than the structurally similar querce-
tin (1E8W.pdb). Nevertheless, since the ATPase sites of RepA 
and DnaB are smaller than the ATP binding site of PIK3, it 
Figure 3. The effect of myricetin on E. coli primase activity in the presence 
(•) and absence (○) of E. coli DnaB helicase. Each data set was normalized 
to the number of primers synthesized in the absence of myricetin. In the ab-
sence of helicase, primase activity was weakly inhibited and poorly fi t but the 
constants were Ymax = 99 ± 2%, IC50 = 700 ± 300 μM myricetin, and an R
2 of 
0.634. DnaB-stimulated primer synthesis could not be fi t to a hyperbolic rela-
tionship so a line was drawn through the data to show the trend. 
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should be possible to design compounds that fi t more snugly 
into their active sites.
New and emerging pathogenic bacteria and the rise in 
multi-drug-resistant bacterial strains are driving the need to 
discover novel antibiotics. Only a few DNA replication en-
zymes are targets for current antibiotics. Bacterial primase and 
DnaB helicase are novel targets that are beginning to generate 
lead compounds from among natural products. In future stud-
ies, we will use structural models of the DnaB helicase active 
site to help engineer myricetin’s structure to improve its selec-
tivity and strength.
4. Materials and methods
4.1. Reagents
The E. coli DnaB helicase and primase were expressed 
and purifi ed as described.58, 12 Ribonucleoside triphosphates 
(NTPs) were from Promega (Madison, WI). Myricetin, mag-
nesium acetate, potassium glutamate, Hepes, and DTT were 
from Sigma (St. Louis, MO). Myricetin was dissolved in eth-
anol and its stock concentration determined using an extinc-
tion coeffi cient at 378 nm of 20,400 M−1 cm−1.59 It was then 
diluted into DMSO for use in the experiments.
4.2. Coupled ATPase assay
ATP hydrolysis by E. coli DnaB was measured by an 
NADH-coupled assay during which ATP was regenerated by 
the combined action of lactate dehydrogenase, pyruvate ki-
nase, and their substrates. 60, 61 The regeneration reaction 
caused the loss of one NADH for every ATP hydrolyzed in 
the primary reaction, such that ATP remained constant while 
NADH declined according to the ATPase activity of DnaB. 
NADH was continuously monitored at its absorption maxi-
mum of 340 nm, and its extinction coeffi cient plus stoichio-
metric factors were used to determine the moles ATP hydro-
lyzed per minute. The reaction buffer was 50 mM Hepes, 
100 mM potassium glutamate, pH 7.5, 10 mM DTT, 400 μM 
NTPs, and 10 mM magnesium acetate.
4.3. Primer synthesis assay
Thermally denaturing HPLC analysis was used to deter-
mine the size, composition, and quantity RNA primers syn-
thesized as previously described.62 Briefl y, RNA primer syn-
thesis reactions were performed in 100 μl nuclease-free water 
reactions containing 50 mM HEPES, 100 mM potassium glu-
tamate, pH 7.5, 10 mM DTT, 400 μM NTPs, and 10 mM mag-
nesium acetate. DnaB helicase (800 nM hexamer) and ssDNA 
template (2 μM) were preincubated to the reaction temper-
ature before the addition of primase (2 μM). HPLC purifi ed 
synthetic ssDNA 23-mer with the sequence 5′-d(CAGACAC
ACACACACTGCACACA)-3′ and with its 3′-end blocked by 
a C3 linker was obtained from Integrated DNA Technologies 
(Coralville, IA). E. coli primase initiates from the d(CTG) tri-
nucleotide underlined in the template sequence. After incuba-
tion at 30 °C for 1 h, the samples were desalted through a Mi-
crospin G-25 column (Amersham, Piscataway, NJ) and then 
separated by thermally denaturing HPLC on a WAVE HPLC 
Nucleic Acid Fragment Analysis System with a DNASep 
HPLC column from Transgenomic (Omaha, NE).
4.4. Data-fi tting
The data were fi t to the indicated equations using Prism 4 
for Macintosh (GraphPad Software, San Diego, CA). 
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